NCIC Clinical Trials Group - Canadian Collaborating Clinical Trials Network

Victoria Harding

The role of miRNAs in regulation and signalling induced by a new oncogenic kinase, LMTK3

Breast

Susan J Ramus

Identifying Prognostic Markers and Therapeutic Targets for Serous Ovarian Cancer

Ovary

Pathology

David Rueda

Single Molecule Imaging

Colorectum Corpus uteri Breast Ovary

Celeste Leigh Pearce

Mechanisms of Prevention of Ovarian Cancer by Oral Contraceptives

Ovary

Pathology

Jane J Kim

Comparative and Cost-Effectiveness of Preventing HPV-Related Diseases

Cervix uteri

Joanne F Dorgan

Prospective Study of Serum MIS and Gynecologic Cancer Risk

Ovary Corpus uteri

Fred R Hirsch

Squamous Cell Carcinoma of the Lung: Validation of Molecular Signatures for Prognosis

Trachea, bronchus and lung

Pathology

Stuart Hogarth

DNA patents beyond clinical genetics: HPV testing and cervical cancer screening in China, the UK and USA. A comparative investigation of the bioethics of biomarker IP and its implications for public p

Oesophagus Cervix uteri Nasopharynx

Ian Tannock

Phase II clinical trial of pantoprazole and docetaxel for men with metastatic castration-resistant prostate cancer

Prostate